Antiproliferative effect of deferiprone on the Hep G2 cell line

Biochemical Pharmacology

Volumn 56, Issue 4, 1998, Pages 431-437

  Chenoufi, Norchen ^a   Drénou, Bernard ^b   Loréal, Olivier ^a   Pigeon, Christelle ^a   Brissot, Pierre ^a,b   Lescoat, Gérard ^a  

^a INSERM   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cell cycle; Deferiprone; Deferoxamine; DNA synthesis; HepG2 cell line; Iron

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRON TRANSPORT; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER CELL CULTURE; PRIORITY JOURNAL;

CELL CYCLE; CELL DIVISION; DNA; HUMANS; IRON; IRON CHELATING AGENTS; PYRIDONES; TUMOR CELLS, CULTURED;

EID: 0345404165     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00071-9     Document Type: Article

References (36)

1. Hann H.W.L., Stahlhut M.W., Blumberg B.S. Iron nutrition and tumor growth Decreased tumor growth in iron deficient mice . Cancer Res. 48:1988;4168-4170.
2. Thompson H.J., Kennedy K., Witt M., Juzefyk J. Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 12:1991;111-114.
3. Kew M.D. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis occurrence in non-cirrhotic patients. Hepatology. 11:1990;1086-1087.
4. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N Engl J Med. 313:1985;1256-1262.
5. Hsing A.W., McLaughlin J.K., Olsen J.H., Mellemkjar L., Wacholder S., Fraumeni J.F. Cancer risk following primary hemochromatosis A population-based cohort study in Denmark . Int J Cancer. 60:1995;160-162.
6. Tarao K., Shimizu A., Ohkawa S., Harada M., Ito Y., Tamai S., Kuni Y. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology. 103:1992;595-600.
7. Ballardini G., Groff P., Zoli M., Bianchi G., Giostra F., Francesconi R., Lenzi M., Zauli D., Cassani F., Bianchi F. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol. 20:1994;218-222.
8. Deugnier Y.M., Charalambous P., Le Quilleuc D., Turlin B., Searle J., Brissot P., Powell L.W., Halliday J.W. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis A study of 185 patients . Hepatology. 18:1993;1363-1369.
9. Turlin B., Juguet F., Moirand R., Lequilleuc D., Loréal O., Campion J.P., Launois B., Ramee M.P., Brissot P., Deugnier Y. Increased liver iron stores in patients with hepatocellular carcinoma developed on a non cirrhotic liver. Hepatology. 22:1995;446-450.
10. Richardson D.R., Baker E. The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta. 1053:1990;1-12.
11. Richardson D.R., Ponka P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med. 124:1994;660-671.
12. Taetle R. The role of transferrin receptors in hemopoietic cell growth. Exp Hematol. 18:1990;360-365.
13. Lederman H.M., Cohen A., Lee J.W., Freedman M.H., Gelfand E.W. Deferoxamine, a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 64:1984;748-753.
14. Hann H.W., Stalhut M.W., Hann C.L. Effect of iron and desferrioxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology. 11:1990;566-569.
15. Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., Gelfand E., Seligman P. Neuroblastoma sensitivity to growth inhibition by desferrioxamine Evidence for a block in G1 phase of the cell cycle . Cancer Res. 53:1993;3968-3975.
16. Donfrancesco A., Deb G., Dominici C., Angioni A., Caniglia M., De sio L., Fidani P., Amici A., Helson L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CEcaT): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol. 15:1992;319-322.
17. Porter J.B. Evaluation of new iron chelators for clinical use. Acta Haematol. 95:1996;13-25.
18. Agarwal M.B., Gupte S.S., Viswanathan C., Vasandani D., Ramanathan J., Desai N., Puniyani R.R., Chablani A.T. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia Indian trial . Br J Haematol. 82:1992;460-466.
19. Olivieri N.F., Brittenham G.M., Matsui D., Berkovitch M., Blendis L.M., Cameron R.G., McClelland R.A., Liu P.P., Templeton D.M., Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 332:1995;918-922.
20. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major proteins and hepatitis B antigen. Science. 209:1980;497-499.
21. Twentymann P.R., Luscombe A. Study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:1987;279-285.
22. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
23. Fargion S., Mandelli C., Piperno A., Cesana B., Fracanzani A.L., Fraquelli M., Bianchi P.A., Firelli G., Conte D. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 15:1992;655-659.
24. Chenoufi N., Loréal O., Drénou B., Cariou S., Hubert N., Leroyer P., Brissot P., Lescoat G. Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J Hepatol. 26:1997;650-658.
25. Reichard P., Ehrenbergn A. Ribonucleotide reductase - a radical enzyme. Science. 221:1983;514-519.
26. Furukawa T., Naitoh Y., Kohno H., Tokunaga R., Taketani S. Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci. 50:1992;2059-2065.
27. Nyholm S., Mann G.J., Johansson A.G., Graslund A., Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 268:1993;26200-26205.
28. Hoyes K.P., Hider R.C., Porter J.B. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res. 52:1992;4591-4599.
29. Lucas J.L., Szepesi A., Domenico J., Takase K., Tordai A., Terada N., Gelfand E.W. Effects of iron depletion on cell cycle progression in normal human T lymphocytes Selective inhibition of the appearance of the cyclin A-associated component of the p33 cdk2 kinase . Blood. 86:1995;2268-2280.
30. Donfrancesco A., Deb G., Dominici C., Pileggi D., Castello M., Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 50:1990;4929-4930.
31. Becton D.L., Roberts B. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res. 49:1989;4809-4812.
32. Hann H., Stahlhut M., Rubin R., Maddrey W. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 70:1992;2051-2056.
33. Bomford A., Isaac J., Roberts S., Edwards A., Young S., Williams R. The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukemia cells. Biochem J. 236:1986;243-249.
34. Louache F., Testa U., Pelicci P., Thomopoulos P., Titeux M., Rochant H. Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem. 259:1984;11576-11582.
35. Theil E.C. Ferritin structure, function and regulation. Adv Inorg Biochem. 9:1983;1-38.
36. Müllner E.W., Neupert B., Kuhn L.C. A specific mRNA binding factor regulates the iron-dependent regulation of transferrin receptor mRNA. Cell. 53:1989;815-825.